JP2007530577A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007530577A5 JP2007530577A5 JP2007505172A JP2007505172A JP2007530577A5 JP 2007530577 A5 JP2007530577 A5 JP 2007530577A5 JP 2007505172 A JP2007505172 A JP 2007505172A JP 2007505172 A JP2007505172 A JP 2007505172A JP 2007530577 A5 JP2007530577 A5 JP 2007530577A5
- Authority
- JP
- Japan
- Prior art keywords
- hydroxy
- aryl
- halogen
- optionally substituted
- alkylene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 36
- 229910052736 halogen Inorganic materials 0.000 claims 34
- 150000002367 halogens Chemical class 0.000 claims 34
- 125000003545 alkoxy group Chemical group 0.000 claims 33
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 32
- 125000003118 aryl group Chemical group 0.000 claims 25
- 150000001875 compounds Chemical class 0.000 claims 23
- 125000002947 alkylene group Chemical group 0.000 claims 21
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 17
- 125000000623 heterocyclic group Chemical group 0.000 claims 14
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 11
- 239000001257 hydrogen Substances 0.000 claims 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 9
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 125000004104 aryloxy group Chemical group 0.000 claims 5
- 239000003433 contraceptive agent Substances 0.000 claims 5
- 230000002254 contraceptive effect Effects 0.000 claims 5
- -1 hydroxy-alkylene- Chemical group 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 102000009132 CB1 Cannabinoid Receptor Human genes 0.000 claims 3
- 108010073366 CB1 Cannabinoid Receptor Proteins 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000011580 syndromic disease Diseases 0.000 claims 3
- 101100240516 Caenorhabditis elegans nhr-10 gene Proteins 0.000 claims 2
- 102000018208 Cannabinoid Receptor Human genes 0.000 claims 2
- 108050007331 Cannabinoid receptor Proteins 0.000 claims 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims 2
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical group C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims 2
- 125000001118 alkylidene group Chemical group 0.000 claims 2
- 230000036528 appetite Effects 0.000 claims 2
- 235000019789 appetite Nutrition 0.000 claims 2
- 125000005098 aryl alkoxy carbonyl group Chemical group 0.000 claims 2
- 239000000812 cholinergic antagonist Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 230000004060 metabolic process Effects 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 239000000583 progesterone congener Substances 0.000 claims 2
- 239000002464 receptor antagonist Substances 0.000 claims 2
- 239000002469 receptor inverse agonist Substances 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- 229960004394 topiramate Drugs 0.000 claims 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
- 102000009135 CB2 Cannabinoid Receptor Human genes 0.000 claims 1
- 108010073376 CB2 Cannabinoid Receptor Proteins 0.000 claims 1
- 102100033868 Cannabinoid receptor 1 Human genes 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 208000008238 Muscle Spasticity Diseases 0.000 claims 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 claims 1
- 230000002921 anti-spasmodic effect Effects 0.000 claims 1
- 229940124575 antispasmodic agent Drugs 0.000 claims 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 claims 1
- 229960000623 carbamazepine Drugs 0.000 claims 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 230000019771 cognition Effects 0.000 claims 1
- 230000008602 contraction Effects 0.000 claims 1
- 230000006735 deficit Effects 0.000 claims 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000000262 estrogen Substances 0.000 claims 1
- 229940011871 estrogen Drugs 0.000 claims 1
- 229960000304 folic acid Drugs 0.000 claims 1
- 235000019152 folic acid Nutrition 0.000 claims 1
- 239000011724 folic acid Substances 0.000 claims 1
- 229960002870 gabapentin Drugs 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000004410 intraocular pressure Effects 0.000 claims 1
- 229940125425 inverse agonist Drugs 0.000 claims 1
- 229960001848 lamotrigine Drugs 0.000 claims 1
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 claims 1
- 239000002207 metabolite Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000037023 motor activity Effects 0.000 claims 1
- 230000004112 neuroprotection Effects 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 229940127234 oral contraceptive Drugs 0.000 claims 1
- 239000003539 oral contraceptive agent Substances 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 229960002036 phenytoin Drugs 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000000018 receptor agonist Substances 0.000 claims 1
- 229940044601 receptor agonist Drugs 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 239000000779 smoke Substances 0.000 claims 1
- 201000009032 substance abuse Diseases 0.000 claims 1
- 231100000736 substance abuse Toxicity 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 claims 1
- 229960000604 valproic acid Drugs 0.000 claims 1
- 230000004580 weight loss Effects 0.000 claims 1
- ZSDQUVCCRVSHNN-UHFFFAOYSA-O CCOC(C(CC1)CC(C(C(NC2C(C)(CC3)CC3C2(C)C)=O)=[NH2+])=C1NC1CCCCC1)=O Chemical compound CCOC(C(CC1)CC(C(C(NC2C(C)(CC3)CC3C2(C)C)=O)=[NH2+])=C1NC1CCCCC1)=O ZSDQUVCCRVSHNN-UHFFFAOYSA-O 0.000 description 1
- SVSATFKHXUZCDS-UHFFFAOYSA-N O=C(c1n[n](C2CCCCC2)c2c1CCCC2Cl)NC1C2C34C1CC3CC4C2 Chemical compound O=C(c1n[n](C2CCCCC2)c2c1CCCC2Cl)NC1C2C34C1CC3CC4C2 SVSATFKHXUZCDS-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55589004P | 2004-03-24 | 2004-03-24 | |
| US60/555,890 | 2004-03-24 | ||
| PCT/US2005/009819 WO2005095353A1 (en) | 2004-03-24 | 2005-03-23 | Tetrahydro-indazole cannabinoid modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007530577A JP2007530577A (ja) | 2007-11-01 |
| JP2007530577A5 true JP2007530577A5 (enExample) | 2008-04-24 |
| JP4825792B2 JP4825792B2 (ja) | 2011-11-30 |
Family
ID=34965110
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007505172A Expired - Fee Related JP4825792B2 (ja) | 2004-03-24 | 2005-03-23 | テトラヒドロ−インダゾールカンナビノイドモジュレーター |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US7452997B2 (enExample) |
| EP (1) | EP1735286B1 (enExample) |
| JP (1) | JP4825792B2 (enExample) |
| CN (1) | CN1956964B (enExample) |
| AR (1) | AR048341A1 (enExample) |
| AT (1) | ATE540027T1 (enExample) |
| AU (1) | AU2005228868B2 (enExample) |
| BR (1) | BRPI0509207A (enExample) |
| CA (1) | CA2561305C (enExample) |
| CR (1) | CR8701A (enExample) |
| DK (1) | DK1735286T3 (enExample) |
| EA (1) | EA010887B1 (enExample) |
| EC (1) | ECSP066877A (enExample) |
| ES (1) | ES2378071T3 (enExample) |
| IL (1) | IL178290A0 (enExample) |
| MX (1) | MXPA06011017A (enExample) |
| NO (1) | NO20064810L (enExample) |
| PL (1) | PL1735286T3 (enExample) |
| PT (1) | PT1735286E (enExample) |
| TW (1) | TW200602324A (enExample) |
| WO (1) | WO2005095353A1 (enExample) |
| ZA (1) | ZA200608808B (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2875230A1 (fr) * | 2004-09-13 | 2006-03-17 | Sanofi Aventis Sa | Derives de pyrazole condense, leur preparation et leur application en therapeutique |
| US7888381B2 (en) | 2005-06-14 | 2011-02-15 | Bristol-Myers Squibb Company | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity, and use thereof |
| RS51298B (sr) * | 2005-09-23 | 2010-12-31 | Janssen Pharmaceutica N.V. | Modulatori heksahidro-ciklooktil pirazol kanabinoida |
| CA2623745A1 (en) * | 2005-09-23 | 2007-04-05 | Janssen Pharmaceutica N.V. | Hexahydro-cycloheptapyrazole cannabinoid modulators |
| CA2623803A1 (en) | 2005-09-23 | 2007-03-29 | Janssen Pharmaceutica N.V. | Tetrahydro-cyclopentyl pyrazole cannabinoid modulators |
| WO2007038045A1 (en) * | 2005-09-23 | 2007-04-05 | Janssen Pharmaceutica, N.V. | Tetrahydro-indazolyl cannabinoid modulators |
| US8378117B2 (en) * | 2005-09-23 | 2013-02-19 | Janssen Pharmaceutica N.V. | Hexahydro-cycloheptapyrazole cannabinoid modulators |
| US8378096B2 (en) | 2005-09-23 | 2013-02-19 | Janssen Pharmaceutica N.V. | Hexahydro-cycloheptapyrazole cannabinoid modulators |
| US7825151B2 (en) * | 2005-09-23 | 2010-11-02 | Janssen Pharmaceutica Nv | Hexahydro-cyclooctyl pyrazole cannabinoid modulators |
| US7795294B2 (en) | 2006-02-14 | 2010-09-14 | Janssen Pharmaceutica N.V. | Tetrahydro-2H-indazole pyrazole cannabinoid modulators |
| US20070254911A1 (en) * | 2006-03-27 | 2007-11-01 | Mingde Xia | Tetrahydro-Pyrazolo[3,4-c]Pyridine Cannabinoid Modulators |
| US8012957B2 (en) | 2006-03-27 | 2011-09-06 | Janssen Pharmaceutica Nv | Tetrahydro-1H-1,2,6-triaza-azulene cannabinoid modulators |
| WO2008054508A2 (en) * | 2006-04-13 | 2008-05-08 | Alza Corporation | Stable nanosized amorphous drug |
| CN101573339A (zh) * | 2006-11-03 | 2009-11-04 | 格兰马克药品股份有限公司 | 作为大麻素受体配体的桥接二环吲唑 |
| EP1935420A1 (en) * | 2006-12-21 | 2008-06-25 | Merck Sante | 2-Adamantyl-butyramide derivatives as selective 11beta-HSD1 inhibitors |
| AU2008229264A1 (en) * | 2007-03-21 | 2008-09-25 | Janssen Pharmaceutica N.V. | Method for treating CB2 receptor mediated pain |
| AU2008229265A1 (en) * | 2007-03-21 | 2008-09-25 | Janssen Pharmaceutica N.V. | Method for treating CB2 receptor mediated pain |
| UA100120C2 (en) | 2007-04-03 | 2012-11-26 | Анадис Фармасьютикалз, Инк. | 5,6-dihydro-1h-pyridin-2-one compounds |
| US8338623B2 (en) * | 2007-07-09 | 2012-12-25 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
| US7943653B2 (en) * | 2007-08-13 | 2011-05-17 | Janssen Pharmaceutica N.V. | Substituted 5-vinylphenyl-1-phenyl-pyrazole cannabinoid modulators |
| AU2009203549B2 (en) * | 2008-01-08 | 2013-03-07 | Purdue Pharma L.P. | Proline Analogs as ligands for cannabinoid receptors for the treatment of pain |
| US20090215850A1 (en) * | 2008-02-27 | 2009-08-27 | Mingde Xia | Method for treating cb2 receptor mediated pain |
| CN102164899B (zh) * | 2008-09-25 | 2014-11-26 | 霍夫曼-拉罗奇有限公司 | 用作抗异常脂肪血症及相关疾病的fxr调节剂的取代的吲唑或四氢吲唑类 |
| US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
| US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
| US10435375B2 (en) | 2015-05-05 | 2019-10-08 | Northwestern University | CXCR4 chemokine receptor modulators |
| WO2017034872A1 (en) * | 2015-08-25 | 2017-03-02 | Janssen Pharmaceutica Nv | Indazole derivatives useful as cb-1 inverse agonists |
| CN105367498B (zh) * | 2015-11-11 | 2019-05-17 | 中国农业大学 | 吡唑并环-3-甲酰胺类似物及其制备和应用 |
| CN106397218A (zh) * | 2016-09-04 | 2017-02-15 | 王际菊 | S‑α‑环己基苯甲胺 |
| US20210253562A1 (en) * | 2018-07-03 | 2021-08-19 | Janssen Pharmaceutica Nv | Acylsufonamide compounds useful as ep3 receptor antagonists |
| TWI768465B (zh) * | 2019-09-12 | 2022-06-21 | 大陸商四川海思科製藥有限公司 | 四氫吲唑衍生物及其製備 |
| TWI768464B (zh) * | 2019-09-12 | 2022-06-21 | 大陸商四川海思科製藥有限公司 | 三環吡唑衍生物及其製備 |
| CN119431335A (zh) * | 2020-06-11 | 2025-02-14 | 贝达药业股份有限公司 | 双环化合物及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1052111B (it) * | 1972-02-29 | 1981-06-20 | Acraf | Acidi i benzil i h indazol 3 carbossilici sostituiti e loro derivati |
| US3895025A (en) * | 1973-03-29 | 1975-07-15 | Du Pont | 2-Benzimidazolethiol preparation |
| US4851425A (en) * | 1985-06-14 | 1989-07-25 | The Upjohn Company | Cyclopentapyrazole and tetrahydroindazole compounds and their use as anti-inflammatory and anti-allergic agents |
| US4861777A (en) * | 1987-09-11 | 1989-08-29 | Mitsubishi Kasei Corporation | Pyrazole derivative and insecticidal and miticidal composition containing the derivative as active ingredient |
| JPH06306053A (ja) * | 1993-01-29 | 1994-11-01 | Sagami Chem Res Center | ３−アゾールカルボン酸誘導体の製造方法及びその中間体 |
| US5532237A (en) * | 1995-02-15 | 1996-07-02 | Merck Frosst Canada, Inc. | Indole derivatives with affinity for the cannabinoid receptor |
| US6410533B1 (en) * | 2000-02-10 | 2002-06-25 | Genzyme Corporation | Antibacterial compounds |
| EP1254115A2 (en) * | 2000-02-11 | 2002-11-06 | Bristol-Myers Squibb Company | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases |
| CA2464333C (en) * | 2001-10-26 | 2011-07-26 | University Of Connecticut | Heteroindanes: a new class of potent cannabimimetic ligands |
| CA2480856A1 (en) | 2002-04-05 | 2003-10-23 | Merck & Co., Inc. | Substituted aryl amides |
| US7145012B2 (en) * | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
-
2005
- 2005-03-23 BR BRPI0509207-8A patent/BRPI0509207A/pt not_active IP Right Cessation
- 2005-03-23 US US11/087,943 patent/US7452997B2/en not_active Expired - Fee Related
- 2005-03-23 CN CN2005800160828A patent/CN1956964B/zh not_active Expired - Fee Related
- 2005-03-23 TW TW094108873A patent/TW200602324A/zh unknown
- 2005-03-23 DK DK05732229.9T patent/DK1735286T3/da active
- 2005-03-23 ES ES05732229T patent/ES2378071T3/es not_active Expired - Lifetime
- 2005-03-23 CA CA2561305A patent/CA2561305C/en not_active Expired - Fee Related
- 2005-03-23 AT AT05732229T patent/ATE540027T1/de active
- 2005-03-23 AU AU2005228868A patent/AU2005228868B2/en not_active Ceased
- 2005-03-23 MX MXPA06011017A patent/MXPA06011017A/es unknown
- 2005-03-23 WO PCT/US2005/009819 patent/WO2005095353A1/en not_active Ceased
- 2005-03-23 PL PL05732229T patent/PL1735286T3/pl unknown
- 2005-03-23 EP EP05732229A patent/EP1735286B1/en not_active Expired - Lifetime
- 2005-03-23 EA EA200601760A patent/EA010887B1/ru not_active IP Right Cessation
- 2005-03-23 PT PT05732229T patent/PT1735286E/pt unknown
- 2005-03-23 JP JP2007505172A patent/JP4825792B2/ja not_active Expired - Fee Related
- 2005-03-28 AR ARP050101196A patent/AR048341A1/es not_active Application Discontinuation
-
2006
- 2006-09-22 EC EC2006006877A patent/ECSP066877A/es unknown
- 2006-09-25 IL IL178290A patent/IL178290A0/en unknown
- 2006-10-20 CR CR8701A patent/CR8701A/es unknown
- 2006-10-23 ZA ZA200608808A patent/ZA200608808B/en unknown
- 2006-10-23 NO NO20064810A patent/NO20064810L/no not_active Application Discontinuation
-
2008
- 2008-10-08 US US12/247,263 patent/US20090099143A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007530577A5 (enExample) | ||
| US10682354B2 (en) | Compositions and methods | |
| JP2005537268A5 (enExample) | ||
| JP4938905B2 (ja) | 選択的ｓ１ｐ１レセプターアゴニストの投与法 | |
| JP2010174019A5 (enExample) | ||
| RU2007120454A (ru) | Производные хинуклидина и их применение в качестве антагонистов мускариновых рецепторов м3 | |
| JP2007515468A5 (enExample) | ||
| JP2009533343A5 (enExample) | ||
| JP2007519649A5 (enExample) | ||
| JP2007536241A (ja) | 糖尿病性腎症の処置のためのａ２ａアデノシンレセプターアゴニスト | |
| MX2010012245A (es) | Medicina que consiste del uso concomitante o combinacion de un inhibidor de dpp-iv y otra medicina para diabeticos. | |
| JP2006503850A5 (enExample) | ||
| JP2017522352A5 (enExample) | ||
| US9333199B2 (en) | Methods of treatment of histamine H-4 receptor-related pruritus associated with nerve disorders | |
| ATE455756T1 (de) | Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung | |
| JP2006518731A5 (enExample) | ||
| JP2003519228A5 (enExample) | ||
| KR20210074315A (ko) | P2x3 길항제를 사용한 소양증의 치료 | |
| JP5425229B2 (ja) | Ｎｋ受容体アンタゴニストの使用 | |
| CN101583362B (zh) | 当以乳清酸盐衍生物给药时降低甲氨蝶呤副作用和毒性的组合物和方法 | |
| JP2008526953A (ja) | 炎症性疾患のプラジカンテルでの治療 | |
| MXPA04004572A (es) | Metodo para el tratamiento de enfermedades autoinmunes. | |
| US20090281143A1 (en) | Dose Reduction of a Cannabinoid CB1 Receptor Antagonist in the Treatment of Overweight or Obesity | |
| CN1142777C (zh) | 噁唑烷酮衍生物在治疗牛皮癣、关节炎和减少癌症化学疗法毒性中的应用 | |
| US6333345B1 (en) | Methods of using and compositions comprising N-desmethylzolpidem |